HUTCHMED's recent financial performance has been heavily influenced by one-time licensing milestones, with TTM revenue declining 12.7% to $1.4B and net income spiking to $227.5M in 2025Q1-Q2 before normalizing to $8.0M in 2026Q2. The company's core operations ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $0.05-68.3% vs $0.14 | $278M-8.5% vs $304M |
Q3 2026 Jul 2, 2026 | $0.05+112.8% vs -$0.36 | $139M+71.9% vs $81M |
Q2 2026 Mar 5, 2026 | $0.00-100.0% vs $2.50 | $271M-6.7% vs $291M |
Q3 2025 Aug 7, 2025 | $2.60+78.1% vs $1.46 | $278M-15.9% vs $330M |
Lexicon Pharmaceuticals NASDAQ: LXRX said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027.
Workday Named a Leader in Inaugural 2026 Gartner Magic Quadrant⢠for Workforce Management TechnologyPR NewswirePLEASANTON, Calif., Sept. 17, 2026Workday Uni
HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfront payment, according to Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng.
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript
Benchmark HCM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for HUTCHMED (China) Limited (HCM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.37 | $2.51B | 5.53 | -12.73% | 83.3% | 45.29% | — | |
| $26.44 | $2.99B | -16.53 | 15.33% | -41.86% | -27.43% | — | |
| $18.45 | $3.41B | -11.53 | 64.04% | -7.21% | -8.7% | — | |
| $0.39 | $279.43M | -0.86 | 96.69% | -67.79% | -80.25% | — | |
| $265.30 | $468.73B | 111.94 | 8.57% | 9.81% | — | — | |
| $148.11 | $365.81B | 20.34 | 1.18% | 4.78% | 6.59% | — |
HUTCHMED (China) Limited (HCM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when HCM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HUTCHMED (China) Limited (HCM) stock FAQ — growth, dividends, profitability & financials explained
HUTCHMED (China) Limited (HCM) reported $549.1M in revenue for fiscal year 2025. This represents a 1350% increase from $37.9M in 2005.
HUTCHMED (China) Limited (HCM) saw revenue decline by 12.7% over the past year.
Yes, HUTCHMED (China) Limited (HCM) is profitable, generating $17.9M in net income for fiscal year 2025 (83.3% net margin).
HUTCHMED (China) Limited (HCM) has a return on equity (ROE) of 45.3%. This is excellent, indicating efficient use of shareholder capital.
HUTCHMED (China) Limited (HCM) generated $9.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
